RUNX1 and therapy-related myeloid neoplasm: Takahashi et al. [45], comparing 14 t-MN cases with 54 age-matched controls with lymphoma with a follow-up time of at least 5 years, detected CHIP in 71% of t-MN patients compared to 31% of controls (p = 0.008), with mutations in RUNX1, TP53, SRSF2 and TET2 genes more commonly observed in patients who developed t-MN.